Treatment of Opioid Use Disorder in the Incarcerated Population

Authors

Shea Goudreau, University of LynchburgFollow

Specialty

Family Practice (Primary Care)

Advisor

Dr. Mary Walton

Abstract

ABSTRACT

The treatment of opioid use disorder in correctional medicine is a relatively novel concept that has become increasingly adopted over the last several years across the United States. Daily sublingual buprenorphine has been widely accepted as a first-line medication; however, the long-acting injectable formulation of buprenorphine may be a more effective option for treating incarcerated patients. The long-acting formulation of buprenorphine is superior to daily sublingual buprenorphine in terms of patient compliance and treatment retention post-release, less frequent dosing, decreased diversion risk in the prison, and reduced patient care episodes as well as staff involvement following the initiation of care.

Recommended Citation

Goudreau S. Treatment of Opioid Use Disorder in the Incarcerated Population. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2023; 5(1).